Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- MHLW Begins Drafting Manual on Proper Use of Antibiotics for Clinicians
December 21, 2016
- Quarterly Price Reviews for Indication-Added Drugs Likely to Get Underway in FY2017, Annual Scheme in FY2018: Officials
December 21, 2016
- Four Ministers Map Out Basic Policy for Drug Pricing Revamp
December 21, 2016
- Basic Policy for Drastic Reform of Drug Pricing System
December 20, 2016
- MHLW OKs Tecfidera, Otezla, Other Drugs
December 20, 2016
- Natural Rise in Social Security Spending to Be Curbed to 500 Billion Yen
December 20, 2016
- Govt Clarifies Its Goals in Healthcare R&D Plan, Aims to Begin Clinical Trials for iPS-Based Therapies by 2020
December 19, 2016
- Chuikyo Kicks Off Debates on 2018 Dual Reform of Healthcare and Long-Term Care Insurance
December 15, 2016
- HIV Med Descovy OK’ed for NHI Price Listing on Dec. 21
December 15, 2016
- PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
December 15, 2016
- MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
December 14, 2016
- Diet members Aim to Create Non-Partisan Forum for Healthcare Industry
December 14, 2016
- Survey Method, Product Scope for Annual Revisions to Be Discussed in 2017
December 14, 2016
- LDP Health Panel Chair Submits Letter Opposing Annual Price Revisions
December 13, 2016
- PMDA Reviewing Risk of Hep B Virus Reactivation for Revlimid
December 13, 2016
- MHLW Announces 16 APIs as Candidates for Switch-OTC Status: None for Lifestyle Diseases
December 13, 2016
- MHLW Panel Recommends 3 Products Including Talion for Approval as “Behind-the-Counter Drugs”
December 13, 2016
- Balance between Survey Costs and Price Gap Important, Shiozaki Says on Annual Revisions
December 12, 2016
- HIV Med Descovy Approved in Japan
December 12, 2016
- Industry Casts Doubt on “1.25 Times” Threshold for Downward Tweak under Foreign Price Adjustment Rule
December 12, 2016
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…